Background: Bibliometric analysis is important for guiding future research priorities. We evaluated the most relevant scientific research on coronavirus disease 2019 (COVID-19) and older adults, analyzed current hot topics, and identified the 50 most cited publications.Methods: Articles published between December 2019 and March 17, 2021 were identified using the search terms “COVID-19” or “Novel Coronavirus” or “SARS-CoV-2” or “2019-nCoV” and “geriatrics” or “older adults” or “elderly” appearing in the title, abstract, keywords, or keywords plus. Original research articles, reviews, editorial materials, and letters were included. Information on articles year, journal, title, author, country, affiliation, keywords, document type, and counts of citations was collected. VOSviewer was used to analyze keywords.Results: A total of 784 publications were included. The most common keywords were “COVID-19” and “older adults,” which were strongly related to “social isolation,” “dementia,” “mortality,” and “loneliness.” The most active (40.8%) and most cited (1,578) country was the United States. The Journal of the American Geriatric Society had the largest number of publications (22.7%) and citations (947). The most researched (84.0%) and most cited areas were geriatrics-gerontology (2,882). The median number of citations for the most cited 50 articles was 46.8. Conclusion: The results of the bibliometric analysis provided information about the quality and research areas of published studies on COVID-19 and older adults. Social and psychological support, nutrition, vaccines, and telemedicine may be hot research topics for the future.

Because of the senescence of the immune system, antibody response to the COVID‐19 vaccines may differ from older to younger adults. The study aim compares the titers of SARS‐CoV‐2 IgG antibody of patients ≥60 years who received three doses of CoronaVac vaccine and those who received two doses of CoronaVac+1 dose of Pfizer‐BioNTech after 1 month of the last vaccination. Patients ≥60 years who received the CoronaVac vaccine between March 1, 2021, and April 30, 2021, who did not have COVID‐19 disease before the first dose of vaccination and were negative for COVID‐19 antibodies, whose antibodies were tested before the third dose of vaccination, and who did not have any COVID‐19 disease during the follow‐up were included. The demographic characteristics and comorbidities of patients were recorded. An immunofluorescence assay (IFA) fast test and a chemiluminescent microparticle immunoassay (Abbott) were used to measure SARS‐CoV‐2 quantitative antibody levels at the first month after the third‐dose vaccine. Totally 81 patients, 41 patients in third dose of the CoronaVac group (female:male 18:23, mean age 69.4 ± 8.5), and 40 patients in third dose of the Pfizer‐BioNTech group (female:male 15:25, mean age 69.9 ± 9.1) were included. The patients' comorbidities in the groups were similar. The titers of IgG antibodies to SARS‐CoV‐2 measured according to both IFA and Abbott Kit at first month the third dose vaccination was significantly higher in the Pfizer‐BioNTech group ( p ≥ 0.001, p = 0.012, respectively). The results report that the formed immunity in the first month after the two doses of CoronaVac+1 dose Pfizer‐BioNTech vaccine was higher than three doses of CoronaVac vaccine in older adults.

Background/aim: We aimed to investigate the factors affecting the mortality of patients aged 65 years or older who were hospitalized with the diagnosis of new coronavirus pneumonia (COVID-19). Materials and methods: This is a retrospective study of patients 65 years old or older with COVID-19 who were hospitalized in Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital, between March 11 and May 28, 2020. Demographic, clinical, treatment, and laboratory data were extracted from electronic medical records. We used univariate and multivariate logistic regression methods to explore the risk factors for in-hospital death. Results: A total of 218 patients (112 men, 106 women) were included, of whom 166 were discharged and 52 died in hospital. With univariate analysis, various clinical features and laboratory variables were found to be significantly different (i.e. P < 0.05). In multivariate logistic regression analysis the following were independently associated with mortality: present malignancy [odds ratio (OR) = 4.817, 95% confidence interval (CI) = 1.107-20.958, P: 0.036]; dyspnea (OR = 4.652, 95% CI = 1.473-14.688, P: 0.009); neutrophil/lymphocyte ratio (NLR; OR = 1.097, 95% CI = 1.012-1.188, P: 0.025); the highest values of C-reactive protein (CRP; OR = 1.006, 95% CI = 1.000-1.012, P: 0.049), lactate dehydrogenase (LDH; OR = 1.002, 95% CI = 1.001-1.004, P: 0.003), and creatinine levels (OR = 1.497, 95% CI = 1.126-1.990, P: 0.006); oxygen saturation (SpO2) values on admission (OR = 0.897, 95% CI = 0.811-0.993, P: 0.036); and azithromycin use (OR = 0.239, 95% CI = 0.065-0.874, P: 0.031). Conclusion: The presence of malignancy; symptoms of dyspnea; high NLR; highest CRP, LDH, and creatinine levels; and low SpO2 on admission predicted mortality. On the other hand, azithromycin use was found to be protective against mortality. Knowing the causes predicting mortality will be important to treat future cases more successfully.

High antibody titers have been found to correlate with the severity of coronavirus disease 2019 (COVID‐19) disease. Therefore, antibody titers may be higher in older adults, whose disease is known to have a more severe course than younger ones. This study aimed to compare the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) immunoglobulin G (IgG) antibody level in the reverse transcription‐polymerase chain reaction (RT‐PCR) to test positive older adults with young. Patients aged ≥18 with positive RT‐PCR and checked serum IgG antibodies between November 1, 2020 and January 13, 2021 were included. The IgG antibody levels and the time between RT‐PCR positivity with the antibody levels were recorded. A total of 1071 patients were divided into two groups as Group 1 <60 years old (n = 902) and Group 2 ≥60 years old (n = 169). The SARS‐CoV‐2 IgG antibody titers were higher in Group 2 (p = 0.001). This height was present in the first 3 months after positive RT‐PCR. While the antibody titers were compared by dividing Group 2 into the three groups according to age ranges (60–69, 70–79, and ≥80 years), the antibody titer was higher in ≥80 years patients (p = 0.044). High COVID‐19 IgG antibody levels may be associated with the severity of the disease. Also, the humoral immunity advantage was seen in the first 3 months in the older patients, which suggests that older adults with COVID‐19 may develop reinfection in the long term.